共 106 条
[1]
Lictenstein GR(2009)ACG practice guidelines: Management of Crohn's Disease in Adults Am J Gastroenterol 104 465-483
[2]
Hanauer SB(2004)Management of refractory inflammatory bowel disease Gastroenterol Clin N Am. 33 319-334
[3]
Sandborn WJ(2010)Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease N Engl J Med 362 1383-95
[4]
Solem CA(2004)Balancing the risks and benefits of inflixmab in the treatment of inflammatory bowel disease Gut. 53 780-782
[5]
Loftus EV(2009)Infliximab prevents Crohn's disease recurrence after ileal resection Gastroenetrology 136 441-30
[6]
Colombel JF(2007)Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial Gastroenterology. 132 52-65
[7]
Sandborn WJ(2003)Natalizumab for Active Crohn's Disease N Engl J Med 348 24-32
[8]
Reinisch W(2007)Certolizumab Pegol for the Treatment of Crohn's Disease N Engl J Med 357 228-38
[9]
Mantzaris GJ(2004)Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy Am J Gastroenterol. 99 878-83
[10]
Kornbluth A(2008)Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients J Gastrointest Surg. 12 1738-44